Technical Analysis for PTN - Palatin Technologies, Inc.

Grade Last Price % Change Price Change
F 3.86 -3.02% -0.12
PTN closed down 1.0 percent on Friday, February 3, 2023, on 55 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Feb 13
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -3.02%
Doji - Bullish? Reversal -3.02%
Stochastic Reached Oversold Weakness -3.02%
Oversold Stochastic Weakness -3.02%
Shooting Star Candlestick Bearish -3.98%
20 DMA Support Bullish -3.98%
Wide Bands Range Expansion -3.98%
20 DMA Support Bullish -5.16%
Wide Bands Range Expansion -5.16%
MACD Bearish Signal Line Cross Bearish -3.02%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 5 hours ago
Fell Below Previous Day's Low about 6 hours ago
Down 2 % about 6 hours ago
20 DMA Resistance about 6 hours ago
Down 1% about 6 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Dysfunction Endocrine System Obesity Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity

Is PTN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.0
52 Week Low 2.14
Average Volume 74,490
200-Day Moving Average 6.08
50-Day Moving Average 3.58
20-Day Moving Average 4.06
10-Day Moving Average 4.11
Average True Range 0.44
RSI 53.05
ADX 40.03
+DI 24.95
-DI 10.64
Chandelier Exit (Long, 3 ATRs) 3.69
Chandelier Exit (Short, 3 ATRs) 3.87
Upper Bollinger Bands 4.66
Lower Bollinger Band 3.46
Percent B (%b) 0.43
BandWidth 29.66
MACD Line 0.15
MACD Signal Line 0.18
MACD Histogram -0.0317
Fundamentals Value
Market Cap 915.01 Million
Num Shares 230 Million
EPS 0.15
Price-to-Earnings (P/E) Ratio 26.36
Price-to-Sales 792.23
Price-to-Book 1.34
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.51
Resistance 3 (R3) 4.54 4.40 4.42
Resistance 2 (R2) 4.40 4.27 4.38 4.39
Resistance 1 (R1) 4.19 4.18 4.12 4.16 4.36
Pivot Point 4.05 4.05 4.02 4.03 4.05
Support 1 (S1) 3.84 3.92 3.77 3.81 3.60
Support 2 (S2) 3.70 3.83 3.68 3.57
Support 3 (S3) 3.49 3.70 3.54
Support 4 (S4) 3.46